A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells.

Huong T X Nguyen, Yabin Song, Satendra Kumar, Fu-Sen Liang

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Engineering TME-gated inducible CAR-T cell therapy for solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Huong T X NguyenDepartment of Chemistry, Case Western Reserve University, 2080 Adelbert Road, Cleveland, OH 44106, USA.ORCID 0000-0002-5989-1405

Yabin SongDepartment of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, NM 87106, USA.

Satendra KumarDepartment of Chemistry, Case Western Reserve University, 2080 Adelbert Road, Cleveland, OH 44106, USA.

Fu-Sen LiangDepartment of Chemistry, Case Western Reserve University, 2080 Adelbert Road, Cleveland, OH 44106, USA.ORCID 0000-0002-1793-0824

Funding

Elsa U. Pardee Foundation n/aNIH HHS P30CA04370

6 · The paper itself

Abstract

The potential of chimeric antigen receptor (CAR)-based immunotherapy as a promising therapeutic approach is often hindered by the presence of highly immunosuppressive tumor microenvironments (TME). Combination therapies with either co-administration or built-in expression of additional TME-modulating therapeutic molecules to potentiate the functions of CAR-T cells can cause systemic toxicities due to the lack of control over the delivery of biologics. Here, we present a proof-of-concept engineered platform in human Jurkat T cells that combines CAR with a therapeutic gene circuit capable of sensing

Indexed as

Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-Lymphocytesbeta-GalactosidaseHumansImmunotherapyJurkat CellsNeoplasmsTumor Microenvironmentbeta-GalactosidaseReceptors, Chimeric Antigencancer immunotherapycancer signalCAR-T cellCIPimmunomodulatorssmall moleculesolid tumorstumor microenvironment

Identifiers

PMID39408896

DOI10.3390/ijms251910568

PMCPMC11476998

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.